Description:

ODM derived from http://clinicaltrials.gov/show/NCT00273338

Link:

http://clinicaltrials.gov/show/NCT00273338

Keywords:
Versions (2) ▾
  1. 2/27/12
  2. 4/13/14
Uploaded on:

April 13, 2014

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility DRKS00003880 NCT00273338 Prostate Cancer

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion Criteria
Age >= 18 years
Histopathologically or cytologically proven adenocarcinoma of the prostate
Documented metastatic prostate adenocarcinoma
Documented progression while on androgen ablation therapy detected by rising prostate specific antigen (PSA) and/or imaging
Eastern Cooperative Oncology Group (ECOG) performance status <= 2
Adequate hematologic, renal and hepatic function
Life expectancy >= 3 months
Exclusion Criteria
Prior chemotherapy, except estramustine
Prior chemotherapy with docetaxel
Prior isotope therapy (e.g., strontium-89, samarium-153, etc.)
One or more contraindications to the use of corticosteroids
History of cancer-related hypercalcemia
Medical Concepts